Show Notes
UK case surge has started, R is 3 to 5
https://coronavirus.data.gov.uk
Guy's and St Thomas's Hospital trust
10% off with Covid
Chris Whitty
Omicron wave, going to peak very quickly
Infections doubling every 2 to 3 days
NHS, reduction in supply and increase in demand more records would be broken
Omicron as well as delta?
https://www.bbc.co.uk/news/live/uk-59664383
Number of omicron infections is rising very fast
Delta cases are flat
and that Delta is not going away, but being built on
If doubling time is every 3 days
Christmas Eve, cases + 462,704
Next few days, 2 million testing positive
Forced into 10 days isolation
Their contacts may also be symptomatic
Testing capacity exceeded
(Country currently averaging 790,000 PCR tests a day)
Professor Andrew Hayward (SAGE)
Outbreak spreading faster than tests can keep up
If you think about getting a year's worth of rain over a month, then you're going to get flooding and potentially severe flooding, no matter how much you've shored up your defences
Professor David Spiegelhalter (statistician)
Reduced socialisation will slow spread down
If it kept on this doubling every two days, you get to 11 million on Christmas Day,
and the entire country on New Year's Eve
Now, this is not sensible
Millions of people are going to catch this over the next few weeks and months
That we know that's going to happen
It could be considerably better than last winter, it could be worse
Zoe study
https://covid.joinzoe.com/data#levels-over-time
Official UK data
https://coronavirus.data.gov.uk/details/cases
https://www.lshtm.ac.uk/newsevents/news/2021/modelling-potential-impact-omicron-england
Actual in hospital data
London in hospital data
Majority of cases in London are Omicron
https://coronavirus.data.gov.uk/details/healthcare?areaType=nhsRegion&areaName=London
South Africa now
Cases are rising steeply in all provinces
Cases in the 4th wave are higher than the peaks in all previous waves
Hospitalisations and deaths are not currently following this trend and,
are still relatively low
Most admissions to hospitals are still for unvaccinated people
Pfizer Boosters have been approved and can be given 6 months after full vaccination
The first people will be eligible at the end of December
Black dog I'm living in South Africa.
The masses of our population live in townships and are unvaccinated.
There are no masks or any social distancing ever since the "pandemic" started.
The Elephant 🐘 is in the room and is being ignored.
We're only 25-30% fully vaccinated.
16 seater minibus 🚐 taxis commute the masses of the people daily, no masks or social distancing.
Hospitalizations and deaths are way lower than a year ago.
Natural Immunity needs to come back to the discussion and needs to stop being downplayed or disregarded by the MSM.
World Health Organization
Omicron is spreading across the globe at an unprecedented rate
https://www.bbc.co.uk/news/world-59656385
Dr Tedros Surely, we have learned by now that we underestimate this virus at our peril.
Even if Omicron does cause less severe disease, the sheer number of cases could once again overwhelm unprepared health systems
UK government response to vitamin D deficiency
https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/free-vitamin-d-supplements-for-people-at-high-risk/ Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Dr. John Campbell
Monkeypox virus, seldom reported outside African until now, Uploaded 27-07-22https://www.nejm.org/doi/full/10.1056/NEJMoa2207323?emp=marcom&utm_source=nejmlist&utm_medium=email&utm_campaign=aomev2&utm_content=version-a&ssotoken=U2FsdGVkX19dsxXEVZT5ggLZ3zieDxejeViMkwTigM4Q7ECfBTJmfTXUrKWkbZ3up0jDhhQjYR6OydzgkC%2F1LL8S5l7OuFDLsP2LiBwfKJ3ymNN4hp0Z%2FNASEYMuetIqeQIQ9ETL8BABCQut7e8xEQeWPlduFdyPMYgAugUePHtSEs5rFR%2BGWfFOCIPZs9Wb7aJf%2FyzhvvLSrzqDKmNt4Q%3D%3D&cid=DM1289135_Notable_Articles_Engaged&bid=1085207852Endemic in AfricaCases now worldwideMETHODSFormed an international collaborative group,international case series, presentation, clinical course, outcomes of PCR confirmed infectionsRESULTSWe report 528 infections diagnosed between April 27 to June 24, 2022Cases, 528, at 43 sites in 16 countries98% in gay or bisexual men, 75% were White, 41% had HIVmedian age 38Transmission suspected to have occurred through sexual activity95% of casesPresentation in this series95% rash (with 64% having less than 10 lesions)73% anogenital lesions41% had mucosal lesions(with 54 having a single genital lesion)Common systemic features preceding the rashfever (62%)lethargy (41%)myalgia (31%)headache (27%)lymphadenopathy (56%)Concomitant sexually transmitted infections109 of 377 (29%)Among the 23 people with a clear exposure historymedian incubation period, 7 days (range, 3 to 20)Monkeypox virus DNADetected in 29 of the 32 (in whom seminal fluid was analyzed)ManagementAntiviral treatment given to 5% of cases70 (13%) were hospitalizedMostly for pain managementsevere anorectal pain (21)soft-tissue superinfection (18)pharyngitis limiting oral intake (5)eye lesions (2)acute kidney injury (2)myocarditis (2)infection-control purposes (13)No deaths were reportedCONCLUSIONSMonkeypox manifested with a variety of dermatologic and systemic clinical findings. Need for rapid identification and diagnosis of cases to contain further community spread. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Detection of Messenger RNA COVID-19 Vaccines in Human Breast MilkUploaded 08-10-22https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796427?guestAccessKey=1c13d17c-1c25-4828-b261-9f321e5126a1&utm_source=twitter&utm_medium=social_jamapeds&utm_term=7701881843&utm_campaign=article_alert&linkId=183092079JAMA Pediatrics(September 26, 2022)Initial messenger RNA (mRNA) vaccine clinical trials excluded several vulnerable groups, young children and lactating individualsCurrent FDA website, re children over 6 monthshttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-childrenToday, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine,and the Pfizer-BioNTech COVID-19 Vaccine,for the prevention of COVID-19 to include use in children down to 6 months of age. From the JAMA paperThe US Food and Drug Administration deferred the decision to authorize COVID-19 mRNA vaccines for infants younger than 6 months,until more data are available,because of the potential priming of the children’s immune responses that may alter their immunityThe Centers for Disease Control and Prevention, re breast feeding mothershttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.htmlCOVID-19 vaccination is recommended for all people 6 months and older. This includes people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. Back to the JAMA studyThe Centers for Disease Control and Prevention recommends offering the COVID-19 mRNA vaccines to breastfeeding individualsalthough the possible passage of vaccine mRNAs in breast milk resulting in infants’ exposure at younger than 6 months was not investigated. This study investigated whether the COVID-19 vaccine mRNA can be detected in the expressed breast milk (EBM) of lactating individualsreceiving the vaccination within 6 months after delivery.N =11Moderna mRNA-1273 vaccine (n = 5)Pfizer BNT162b2 vaccine (n = 6)Samples of EBM were collected before vaccination (control),and for 5 days postvaccination. 131 EBM samples were collected(1 hour to 5 days after vaccine administration)The presence of COVID-19 vaccine mRNA in different milk fractionsassayed using 2-step quantitative reverse transcriptase–polymerase chain reaction. ResultsTrace amounts of BNT162b2 and mRNA-1273 COVID-19 mRNA vaccines were detected in 7 samples from 5 different participants,at various times up to 45 hours postvaccinationNo vaccine mRNA was detected in prevaccinationDiscussionThe sporadic presence and trace quantities of COVID-19 vaccine mRNA detected in EBM suggest that breastfeeding after COVID-19 mRNA vaccination is safe,particularly beyond 48 hours after vaccination. These data demonstrate for the first time the biodistribution of COVID-19 vaccine mRNA to mammary cells,and the potential ability of tissue EVs to package the vaccine mRNA that can be transported to distant cells. In ratshttps://www.sciencedirect.com/science/article/abs/pii/S0168365915300535?via%3DihubUp to 3 days following intramuscular administration, low vaccine mRNA levels were detected in the heart, lung, testis, and brain tissues, indicating tissue biodistributionVaccine administration ---- lipid nanoparticles containing the vaccine mRNA ----- mammary glands (hematogenous and/or lymphatic routes)Vaccine mRNA released into mammary cell cytosol ---- recruited into developing EVs ------ secreted in EBMCaution is warranted about breastfeeding children younger than 6 months in the first 48 hours after maternal vaccination until more safety studies are conducted. COVID-19 medical misinformation policyhttps://support.google.com/youtube/answer/9891785Claims about COVID-19 vaccinat Learn more about your ad choices. Visit megaphone.fm/adchoices
@Campbellteaching Learn more about your ad choices. Visit megaphone.fm/adchoices
Bivalent new vaccine, Moderna press releaseUploaded 19-08-22https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspxOmicron-containing bivalent COVID booster candidate, mRNA-1273.214(original mRNA-1273 vaccine),Superior neutralizing antibody responsein baseline seronegative participants. increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. mRNA-1273.214 50 μg booster dose, well-tolerated in the 437 study participantsThe safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of mRNA-1273 50 μgBA.1SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 44 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdfBA.2 3.4% BA.4 17.2% BA.5 78.7%Other 0.7%US variantshttps://covid.cdc.gov/covid-data-tracker/#variant-proportionsBA.5 88.8%BA.4 5.3%BA.4.6 5.1%BA.2.12.1 0.8%BA.2 0%BA.1s 0%Delta 0%Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canadahttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551Population-based cohort study of 297 individuals in Ontario, Canada,with myocarditis or pericarditis following COVID-19 vaccination,found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. The results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccinesFirst bivalent COVID-19 booster vaccine approved by UK medicines regulatorhttps://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulatorModerna bivalent approved for adult booster doses by MHRASpikevax bivalent Original/Omicron25 micrograms targets the original virus strain25 micrograms targets OmicronOmicron (BA.1) and the original 2020 strain(was also found to generate a good immune response against BA.4 and BA.5)Safety monitoringside effects observed were the same as those seen for the original Moderna booster dose,and were typically mild and self-resolving, and no serious safety concerns were identified.Global covid deathshttps://www.worldometers.info/coronavirus/6,466,947Evidence cited by HMRAhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2822%2900320-6/fulltextBased on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million deaths from COVID-19 in 185 countries,between Dec 8, 2020, and Dec 8, 2021. 19·8 million when we used excess deaths as an estimateJoint Committee on Vaccination and Immunisation (JCVI) updated statement on the COVID-19 vaccination programme for autumn 2022For autumn 2022https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022/joint-committee-on-vaccination-and-immunisation-jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022JCVI advisesthe following groups should be offered a COVID-19 booster vaccine:residents in a care home for older adults and staff working in care homes for older adultsfrontline health and social care workersall adults aged 50 years and overpersons aged 5 to 49 years in a clinical risk group persons aged 5 to 49 years who are household contacts of people with immunosuppressionpersons aged 16 to 49 years who are carers Time to collect PROSPECT Learn more about your ad choices. Visit megaphone.fm/adchoices
Confirmation of excess deaths in 2023 for US, UK, Canada, Australia, NZ, Netherlands, and Denmark. However, deaths are lower than expected in Poland, Hungary, and Sweden. Uploaded 24-09-23OECD datahttps://stats.oecd.org/index.aspx?queryid=104676 Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices